Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$63.98 - $85.37 $944,856 - $1.26 Million
14,768 Added 80.28%
33,164 $2.43 Million
Q3 2022

Oct 24, 2022

BUY
$67.99 - $89.57 $1.25 Million - $1.65 Million
18,396 New
18,396 $1.4 Million
Q3 2021

Nov 03, 2021

SELL
$116.17 - $194.55 $108,618 - $181,904
-935 Closed
0 $0
Q2 2021

Jul 30, 2021

BUY
$130.4 - $225.58 $121,924 - $210,917
935 New
935 $207,000
Q1 2021

May 13, 2021

SELL
$124.11 - $190.17 $3.69 Million - $5.65 Million
-29,692 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$112.16 - $174.14 $170,595 - $264,866
-1,521 Reduced 4.87%
29,692 $5.14 Million
Q3 2020

Nov 06, 2020

BUY
$58.05 - $111.31 $25,019 - $47,974
431 Added 1.4%
31,213 $3.47 Million
Q2 2020

Aug 03, 2020

BUY
$57.2 - $74.41 $47,190 - $61,388
825 Added 2.75%
30,782 $1.83 Million
Q1 2020

May 14, 2020

SELL
$57.05 - $95.75 $13.2 Million - $22.2 Million
-231,358 Reduced 88.54%
29,957 $2.02 Million
Q4 2019

Feb 10, 2020

BUY
$68.3 - $93.8 $988,984 - $1.36 Million
14,480 Added 5.87%
261,315 $22 Million
Q3 2019

Nov 12, 2019

SELL
$61.86 - $97.8 $10.2 Million - $16.1 Million
-164,824 Reduced 40.04%
246,835 $18.5 Million
Q2 2019

Aug 07, 2019

BUY
$42.22 - $63.23 $654,452 - $980,128
15,501 Added 3.91%
411,659 $26 Million
Q1 2019

May 13, 2019

BUY
$31.96 - $56.12 $2.03 Million - $3.56 Million
63,491 Added 19.09%
396,158 $19.1 Million
Q4 2018

Feb 13, 2019

SELL
$28.72 - $52.63 $6.22 Million - $11.4 Million
-216,661 Reduced 39.44%
332,667 $11.1 Million
Q3 2018

Nov 08, 2018

BUY
$32.0 - $52.4 $712,736 - $1.17 Million
22,273 Added 4.23%
549,328 $28.8 Million
Q2 2018

Aug 06, 2018

BUY
$19.85 - $32.0 $10.5 Million - $16.9 Million
527,055 New
527,055 $16.5 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.23B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Granite Investment Partners, LLC Portfolio

Follow Granite Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granite Investment Partners, LLC with notifications on news.